Consistent with previous studies [12, 25–27], our study showed that AD risk variants in CR1, CD33, CLU, and SLC24A4/RIN3 affect their gene expression levels in the above key regions for brain regulatory effects. This evidence concerns the gene CD33 and Alzheimer disease.